Rowley Law PLLC is investigating potential securities law violations by Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) and its board of directors concerning the proposed acquisition of the company by Innoviva, Inc. (NASDAQ: INVA). Stockholders will receive $2.20 for each share of Entasis Therapeutics Holdings stock that they hold. Innoviva currently owns approximately 60% of Entasis Therapeutics Holdings common stock. The transaction is valued at approximately $113 million and is expected to close in the third quarter of 2022.
If you are a stockholder of Entasis Therapeutics Holdings Inc. and are interested in obtaining additional information regarding this investigation, please fill in the contact form on this page. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at firstname.lastname@example.org, or by telephone at 914-400-1920 or 844-400-4643 (toll-free).
Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
The submission of this form does not create an attorney-client relationship.